Calcimedica’s Auxora Study: A Potential Game-Changer for AKI Treatment

Calcimedica, Inc. ((CALC)) announced an update on their ongoing clinical study.

Calcimedica, Inc. is conducting a study titled ‘Auxora for the Treatment of AKI and Modulation of Injurious Crosstalk With the Lung: A Randomized Control Trial (KOURAGE).’ The study aims to evaluate the effectiveness of Auxora in treating acute kidney injury (AKI) associated with acute hypoxemic respiratory failure (AHRF). This research is significant as it targets the modulation of harmful interactions between the kidney and lungs, potentially improving outcomes for patients with these conditions.

The intervention being tested is Auxora, an experimental drug administered intravenously. Patients receive five infusions over five days, and the study includes a placebo group for comparison. Auxora is designed to mitigate the effects of AKI and its impact on lung function.

The study follows an interventional design with random allocation and a parallel intervention model. It employs quadruple masking, meaning that participants, care providers, investigators, and outcomes assessors are unaware of the treatment assignments. The primary purpose of the study is treatment-focused.

The study began on April 16, 2024, with the primary completion date yet to be announced. The latest update was submitted on September 12, 2025. These dates are crucial as they mark the progression and current status of the trial.

For investors, this study could impact Calcimedica’s stock performance positively if results show Auxora’s effectiveness, potentially setting the company apart in the pharmaceutical industry. The ongoing research also positions Calcimedica as a key player in developing treatments for complex conditions like AKI and AHRF, which could influence investor sentiment and market dynamics.

The study is currently recruiting, and further details are available on the ClinicalTrials portal.